Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft

被引:0
|
作者
Stavart, Louis [1 ,2 ]
Halfon, Matthieu [1 ,2 ]
Dewarrat, Natacha [3 ]
Rotman, Samuel [4 ]
Golshayan, Dela [1 ,2 ,5 ]
机构
[1] Lausanne Univ Hosp CHUV, Transplantat Ctr, Lausanne, Switzerland
[2] Lausanne Univ Hosp CHUV, Transplantat Immunopathol Lab, Lausanne, Switzerland
[3] Lausanne Univ Hosp CHUV, Serv & Cent Lab Hematol, Lausanne, Switzerland
[4] Lausanne Univ Hosp CHUV, Inst Pathol, Lausanne, Switzerland
[5] Univ Lausanne UNIL, Fac Biol & Med, Lausanne, Switzerland
关键词
chronic lymphocytic leukemia; kidney transplantation; Bruton tyrosine kinase inhibitor; acute cellular rejection; case report; B-CELL LYMPHOCYTOSIS; TRANSPLANTATION; IBRUTINIB; LYMPHOMA; PATIENT; DONOR;
D O I
10.3389/fmed.2024.1451264
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The burden of chronic lymphocytic leukemia (CLL) in the prognosis of solid organ transplant (SOT) recipients seems non-negligible. Whether transplanting a patient with previous CLL is safe or what is the optimal monitoring and treatment management after transplantation is still unclear and only based on few case series and reports. Therefore, we aimed to contribute to this understanding by reporting the first documented case of a clinically significant CLL with biopsy-proven infiltration of the kidney allograft and its successful management with a Bruton tyrosine kinase inhibitor (BTKi). We then reviewed the related literature, with a focus on CLL and kidney transplantation. Our main message is that BTKi may represent a safe and effective intervention to prevent the hazardous patient and graft outcomes of CLL in SOT patients.
引用
收藏
页数:7
相关论文
共 50 条
  • [11] IMPACT OF ACALABRUTINIB THERAPY ON BRUTON'S TYROSINE KINASE LEVELS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Cacciola, Rossella
    Cacciola, Emma
    EXPERIMENTAL HEMATOLOGY, 2023, 124 : S67 - S67
  • [12] Effects of the Bruton's tyrosine kinase inhibitor ibrutinib on humoral immunity in patients with chronic lymphocytic leukemia
    Sun, Clare
    Lee, Yuh Shan
    Lipsky, Andrew
    Farooqui, Mohammed
    Herman, Sarah
    Salem, Dalia
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Aue, Georg
    Wiestner, Adrian
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [13] Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia
    Barrientos, Jacqueline
    Rai, Kanti
    LEUKEMIA & LYMPHOMA, 2013, 54 (08) : 1817 - 1820
  • [14] Bruton tyrosine kinase plays a major role in the development of chronic lymphocytic leukemia
    Boussen, Ines
    Mohty, Mohamad
    HEMATOLOGIE, 2014, 20 (02): : 94 - 95
  • [15] The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia
    Tran, Phu N.
    O'Brien, Susan
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (09) : 1079 - 1088
  • [16] The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia
    Gordon, Max J.
    Danilov, Alexey V.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [17] Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia
    Xiangxing Liu
    Binyi Hu
    Nan Peng
    Liming Chen
    Dingyuan Hu
    Jiaojiao Zhang
    Lijue Wang
    Zhenwei Xie
    Suping Niu
    Qian Lu
    Jin Lu
    Yi Fang
    Clinical and Experimental Medicine, 2023, 23 : 4237 - 4248
  • [18] Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia
    Fang, Yi
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (08) : 4237 - 4248
  • [19] Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia
    Hosier, Gregory W.
    Touma, Naji J.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (05): : E237 - E239
  • [20] Atrial Fibrillation Management and Outcomes in Bruton's Tyrosine Kinase Inhibitor Treated Chronic Lymphocytic Leukemia Patients
    Itchaki, Gilad
    Razi, Talish
    Zoref-Lorenz, Adi
    Ellis, Martin H.
    Arbel, Ronen
    BLOOD, 2024, 144 : 5120 - 5121